JP2016503797A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503797A5
JP2016503797A5 JP2015549717A JP2015549717A JP2016503797A5 JP 2016503797 A5 JP2016503797 A5 JP 2016503797A5 JP 2015549717 A JP2015549717 A JP 2015549717A JP 2015549717 A JP2015549717 A JP 2015549717A JP 2016503797 A5 JP2016503797 A5 JP 2016503797A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015549717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/076592 external-priority patent/WO2014100425A1/en
Publication of JP2016503797A publication Critical patent/JP2016503797A/ja
Publication of JP2016503797A5 publication Critical patent/JP2016503797A5/ja
Withdrawn legal-status Critical Current

Links

JP2015549717A 2012-12-20 2013-12-19 ペリ−カルビノール Withdrawn JP2016503797A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740197P 2012-12-20 2012-12-20
US61/740,197 2012-12-20
PCT/US2013/076592 WO2014100425A1 (en) 2012-12-20 2013-12-19 Peri-carbinols

Publications (2)

Publication Number Publication Date
JP2016503797A JP2016503797A (ja) 2016-02-08
JP2016503797A5 true JP2016503797A5 (lv) 2016-12-28

Family

ID=50979217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015549717A Withdrawn JP2016503797A (ja) 2012-12-20 2013-12-19 ペリ−カルビノール

Country Status (14)

Country Link
US (1) US9604997B2 (lv)
EP (1) EP2935220A4 (lv)
JP (1) JP2016503797A (lv)
KR (1) KR20150118106A (lv)
CN (1) CN105073714A (lv)
AU (1) AU2013361314A1 (lv)
CA (1) CA2896032A1 (lv)
CL (1) CL2015001754A1 (lv)
HK (1) HK1217325A1 (lv)
IL (1) IL239178A0 (lv)
MX (1) MX2015007916A (lv)
RU (1) RU2015120478A (lv)
SG (1) SG11201504859YA (lv)
WO (1) WO2014100425A1 (lv)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
CN117045653A (zh) 2013-01-23 2023-11-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
US10111862B2 (en) 2013-01-25 2018-10-30 Aldeyra Therapeutics, Inc. Traps in the treatment of macular degeneration
BR112018003250A2 (pt) * 2015-08-21 2018-09-25 Aldeyra Therapeutics Inc compostos deuterados e usos dos mesmos
BR112018003264A2 (pt) * 2015-08-21 2018-09-25 Aldeyra Therapeutics Inc conjugados de aldeído e usos dos mesmos
KR20180116416A (ko) 2016-02-28 2018-10-24 알데이라 테라퓨틱스, 아이엔씨. 사이클로덱스트린으로의 알레르기성 안질환의 치료
JP7116490B2 (ja) 2016-05-09 2022-08-10 アルデイラ セラピューティクス, インコーポレイテッド 眼の炎症性障害および疾患の組合せ処置
US20180050989A1 (en) * 2016-08-22 2018-02-22 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and uses thereof
MX2019010576A (es) 2017-03-16 2019-10-07 Aldeyra Therapeutics Inc Compuestos polimorficos y usos de los mismos.
EP3694500A4 (en) 2017-10-10 2021-06-30 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3856478A4 (en) 2018-09-25 2022-06-08 Aldeyra Therapeutics, Inc. FORMULATIONS FOR THE TREATMENT OF DRY EYE DISEASE
JP2022526917A (ja) 2019-03-26 2022-05-27 アルデイラ セラピューティクス, インコーポレイテッド 眼科用製剤およびその使用
US11267788B2 (en) 2020-07-16 2022-03-08 Dermavant Sciences GmbH Isoquinoline compounds and their use in treating AhR imbalance

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
SU509046A1 (ru) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
CA2054339C (en) 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
CA2261916A1 (en) 1996-08-01 1998-02-12 Dowelanco Llc 4-substituted quinoline derivatives having fungicidal activity
ATE336485T1 (de) 1997-05-02 2006-09-15 Schering Ag Substituierte heterocyclen und deren verwendung in arzneimitteln
WO1999046237A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
AU1735001A (en) 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP1610772A4 (en) 2003-03-14 2008-06-18 Univ Washington RETINOID REPLACEMENT AND OPSIN AGONISTS AND METHOD OF USE THEREOF
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
CA2527175A1 (en) 2003-04-18 2004-10-28 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
AU2004293105B2 (en) 2003-11-20 2010-09-09 Othera Holding, Inc. Amelioration of macular degeneration and other ophthalmic diseases
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
EP1722766A2 (en) 2004-02-17 2006-11-22 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
CA2585210A1 (en) * 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
NZ590271A (en) * 2006-04-14 2011-12-22 Prana Biotechnology Ltd 9-hydroxy-3-substituted-4H-pyrido[1,2-a]pyrimidin-4-ones and 9-hydroxy-3-substituted-4H-pyrido[1,2-a]pyrimidin-4-thiones
CN101611009A (zh) * 2006-07-25 2009-12-23 伊维沃制药股份有限公司 喹啉衍生物
MY160052A (en) 2007-10-05 2017-02-15 Acucela Inc Alkoxy compounds for disease treatment
KR20110044291A (ko) 2008-08-12 2011-04-28 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 벤족사졸, 벤즈티아졸 및 관련 유사체
WO2010133672A1 (en) * 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
EP2477594A4 (en) 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
BR112013017943A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores receptores do tipo toll
WO2012105887A1 (en) 2011-01-31 2012-08-09 Tim Bowden Active principle for mitigating undesired medical conditions
CN117045653A (zh) 2013-01-23 2023-11-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
US10111862B2 (en) 2013-01-25 2018-10-30 Aldeyra Therapeutics, Inc. Traps in the treatment of macular degeneration
US10272106B2 (en) 2014-06-04 2019-04-30 Case Western Reserve University Compositions and methods of treating diabetic retinopathy
WO2016085939A2 (en) 2014-11-24 2016-06-02 Case Western Reserve University Compounds and methods of treating ocular disorders

Similar Documents

Publication Publication Date Title
JP2016503797A5 (lv)
JP2016505637A5 (lv)
JP2015505296A5 (lv)
JP2014511891A5 (lv)
JP2017537940A5 (lv)
JP2014511892A5 (lv)
JP2013537203A5 (lv)
JP2012092103A5 (lv)
JP2014521688A5 (lv)
JP2015143283A5 (lv)
JP2013540713A5 (lv)
JP2016515561A5 (lv)
JP2016530259A5 (lv)
JP2013528180A5 (lv)
JP2015504067A5 (lv)
JP2016506960A5 (lv)
JP2019524883A5 (lv)
RU2015120478A (ru) Пери-карбинолы
JP2015501833A5 (lv)
RU2015126015A (ru) Новые улавливатели в лечении макулодистрофии
JP2019516739A5 (lv)
JP2009501745A5 (lv)
JP2013544860A5 (lv)
JP2016505614A5 (lv)
JP2012513416A5 (lv)